Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 5/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12788580 | 0.81 | BCAT2 (0.62) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL1520684 | 0.78 | BCAT2 (0.72) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL26906281 | 0.78 | BCAT2 (0.72) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21523086 | 0.78 | BCAT2 (0.57) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL21523085 | 0.78 | BCAT2 (0.57) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13662555 | 0.78 | RIPK1 (0.58) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL13662572 | 0.78 | BCAT2 (0.57) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4481703 | 0.76 | BCAT2 (0.64) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL9244961 | 0.76 | BCAT2 (0.69) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4481705 | 0.76 | BCAT2 (0.64) | BCAT2NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | BCAT2 3529/4885NPC1 557/4885RAB9A 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.